We recently published a list of 12 Best Quality Stocks to Invest in Now. In this article, we are going to take a look at ...

Biogen believes that some of its new drugs, Leqembi, Skyclarys and Zurzuvae, have the potential to revive long-term growth. Can Biogen achieve this goal?

What's considered excellent revenue growth depends on the industry. With that context in mind, consider that Eli Lilly's ...

US-based Eli Lilly's Kisunla drug and Japanese company Eisai's Leqembi (below), two breakthrough drugs for the diagnosis and ...

Treatment with donanemab (Kisunla) raised the risk of amyloid-related imaging abnormalities (ARIA) in people with early ...

It's hard to trust the disease statistics when cognitive tests often are not completed, write Robert Brownell and Dr. Yogesh ...

Eli Lilly says a new starting dose regimen for its Alzheimer's disease therapy Kisunla reduces the risk of side effects that have stood in the way of approvals and reimbursement decisions for ...

Presiding over the upward trajectory of Eli Lilly over the last eight years is paying off nicely for CEO David Ricks. | ...

Perhaps Eli Lilly's most promising recent approval is Kisunla, an Alzheimer's disease treatment. Despite an aging population, few medicines in this field have earned the green light from ...

RiverPark Advisors, an investment advisory firm and sponsor of the RiverPark family of mutual funds, released its “RiverPark ...

Such tests are increasingly moving beyond their origins in cutting-edge research and into the laboratory and diagnostic ...